ConductScience.org, home

Paper859634

High-LET radiations induce a large proportion of non-rejoining DNA breaks.

Ritter MA and 2 others. Nature, 1977. Cited by 330 papers, by iCite.

Cite this record

ConductScience Library. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Papers, record 859634. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/859634

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High-LET radiations induce a large proportion of non-rejoining DNA breaks.
PubMed
Journal
Nature
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
330
iCite
Relative citation ratio, by iCite
8.51
iCite
Revised in PubMed
2019-06-17
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ritter MAM A
2Cleaver JEJ E
3Tobias CAC A

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell SurvivalMajor topic
DNAMajor topic
Energy TransferMajor topic
Radiation, IonizingMajor topic
Cell Line
Dose-Response Relationship, Radiation
X-Rays

Source PubMed

Download CSV of topics

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 330 citations.

PMIDTitleJournalYearIn PapersSource
42883456Bone Radiopharmaceuticals: Evolution from Palliative Therapy to Targeted Precision Oncology and Theranostics.Biology (Basel)2026https://conductscience.org/library/papers/42883456PubMed
42569093Real-World Outcomes of Combination Therapy With Radium-223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer.Adv Urol2026https://conductscience.org/library/papers/42569093PubMed
41145955In silico assessment of cellular damage from Lu-177, Ac-225, and Pb-212 therapeutic radionuclides.Med Phys2025https://conductscience.org/library/papers/41145955PubMed
39622964The effects of cell displacement on DNA damages in targeted radiation therapy using Geant4-DNA.Sci Rep2024https://conductscience.org/library/papers/39622964PubMed
38921049Simulation of Radiation-Induced DNA Damage and Protection by Histones Using the Code RITRACKS.BioTech (Basel)2024https://conductscience.org/library/papers/38921049PubMed
38481668Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies.BJUI Compass2024https://conductscience.org/library/papers/38481668PubMed
37894414Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.Cancers (Basel)2023https://conductscience.org/library/papers/37894414PubMed
36012698Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model.Int J Mol Sci2022https://conductscience.org/library/papers/36012698PubMed
35657158Genomic biomarkers to guide precision radiotherapy in prostate cancer.Prostate2022https://conductscience.org/library/papers/35657158PubMed
34084750Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.Front Oncol2021https://conductscience.org/library/papers/34084750PubMed
34039648Radium-223-Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow.Mol Cancer Res2021https://conductscience.org/library/papers/34039648PubMed
33882773Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice.Int J Hyperthermia2021https://conductscience.org/library/papers/33882773PubMed
33558017Alpha emitting nuclides for targeted therapy.Nucl Med Biol2021https://conductscience.org/library/papers/33558017PubMed
33142739
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study.
Cancers (Basel)2020https://conductscience.org/library/papers/33142739PubMed
31712765Radium-223 mechanism of action: implications for use in treatment combinations.Nat Rev Urol2019https://conductscience.org/library/papers/31712765PubMed
30775252Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer.Asian J Urol2019https://conductscience.org/library/papers/30775252PubMed
30293905Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.Eur Urol2019https://conductscience.org/library/papers/30293905PubMed
29977175The Lowest Radiation Dose Having Molecular Changes in the Living Body.Dose Response2018https://conductscience.org/library/papers/29977175PubMed
29800455Estimation of the radiation-induced DNA double-strand breaks number by considering cell cycle and absorbed dose per cell nucleus.J Radiat Res2018https://conductscience.org/library/papers/29800455PubMed
28919714Radium 223 dichloride for prostate cancer treatment.Drug Des Devel Ther2017https://conductscience.org/library/papers/28919714PubMed

See all 54 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/859634

GET https://conductscience.org/api/papers/v1/859634/cited_by?page=2